Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gill Mundin

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Pain and Symptom Management|April 2, 2016
Reply to MeijlerAndrew Davies, Gill Mundin,
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 26, 2018
Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteersMartin Jönsson, Gill Mundin, Michael Sumner
Addiction (Abingdon, England)|April 22, 2017
Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversalGill Mundin, Rebecca McDonald, Kevin Smith, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|February 16, 2023
Pharmacokinetic and Pharmacodynamic Comparison of Fluticasone Propionate/Formoterol Fumarate Administered via a Pressurized Metered-Dose Inhaler and a Novel Breath-Actuated Inhaler in Healthy VolunteersSanjeeva Dissanayake, Gill Mundin, Jo Woodward, et al.
Journal of Pain and Symptom Management|December 27, 2015
The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer PainAndrew Davies, Gill Mundin, Joanna Vriens, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 2012
Low absolute bioavailability of oral naloxone in healthy subjectsKevin Smith, Michael Hopp, Gill Mundin, et al.
Clinical Therapeutics|December 26, 2008
Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteersKevin Smith, Michael Hopp, Gill Mundin, et al.
Addiction (Abingdon, England)|November 17, 2017
Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer studyRebecca McDonald, Ulrike Lorch, Jo Woodward, et al.
British Journal of Clinical Pharmacology|June 22, 2021
Pharmacokinetics and brain σ1 receptor occupancy of MR309, a selective σ1 receptor antagonistEugenii A Rabiner, Kevin Smith, Carla Bennett, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 30, 2018
Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label StudyHelen Dooner, Gill Mundin, Sabine Mersmann, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Pain and Symptom Management|April 2, 2016
Reply to MeijlerAndrew Davies, Gill Mundin,
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 26, 2018
Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteersMartin Jönsson, Gill Mundin, Michael Sumner
Addiction (Abingdon, England)|April 22, 2017
Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversalGill Mundin, Rebecca McDonald, Kevin Smith, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|February 16, 2023
Pharmacokinetic and Pharmacodynamic Comparison of Fluticasone Propionate/Formoterol Fumarate Administered via a Pressurized Metered-Dose Inhaler and a Novel Breath-Actuated Inhaler in Healthy VolunteersSanjeeva Dissanayake, Gill Mundin, Jo Woodward, et al.
Journal of Pain and Symptom Management|December 27, 2015
The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer PainAndrew Davies, Gill Mundin, Joanna Vriens, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 2012
Low absolute bioavailability of oral naloxone in healthy subjectsKevin Smith, Michael Hopp, Gill Mundin, et al.
Clinical Therapeutics|December 26, 2008
Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteersKevin Smith, Michael Hopp, Gill Mundin, et al.
Addiction (Abingdon, England)|November 17, 2017
Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer studyRebecca McDonald, Ulrike Lorch, Jo Woodward, et al.
British Journal of Clinical Pharmacology|June 22, 2021
Pharmacokinetics and brain σ1 receptor occupancy of MR309, a selective σ1 receptor antagonistEugenii A Rabiner, Kevin Smith, Carla Bennett, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 30, 2018
Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label StudyHelen Dooner, Gill Mundin, Sabine Mersmann, et al.
Pageof 2